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Incidentally discovered adrenal masses are very common given the increased number of imaging studies performed in recent
years. We here report a clinical case of a 20-year-old woman who presented with left flank pain. Ultrasound examination revealed
a contralateral adrenal mass, which was confirmed at computed tomography (CT) scan. Hormonal hypersecretion was excluded.
Given the size (11 × 10 × 7 cm) and the uncertain nature of the mass, it was surgically removed and sent for pathological analyses.
Conclusive diagnosis was ganglioneuroblastoma. Ganglioneuroblastoma is an uncommon malignant tumor, extremely rare in
adults, particularly in females. This neoplasm is frequently localized in adrenal gland.
1. Introduction
One of the most common unexpected findings revealed by
imaging studies is an adrenal mass, called incidentaloma,
which occurs in about 2–4% of the radiological studies per-
formed for other reasons [1]. The preliminary evaluation of
the mass is aimed to distinguish benign from malign lesions
and to exclude hormonal hypersecretion. Most adrenal
masses are small nonfunctioning adrenocortical adenomas,
which do not require treatment or follow-up. Nevertheless,
if the mass shows hormonal hypersecretion or malignancy is
suspected, surgery is recommended [2].
Ganglioneuroblastoma (GNB) represents a rare cause of
adrenal tumor in adults. Preoperative suspicion is challenging
and the final diagnosis is often made by the pathologist after
surgical removal.
2. Case Presentation
A 20-year-old Caucasian woman was admitted through the
Emergency Department for right flank pain. Abdominal
ultrasound examination was performed and a contralat-
eral adrenal mass was incidentally found. Subsequently, the
patient underwent computed tomography (CT) to confirm
the finding.Themass in left adrenal lodge was solid andmea-
sured 11 × 10 × 7 cm, showing heterogeneous density (varying
17–40HU) and calcifications (Figure 1). Dynamic analysis
revealed a progressive and modest contrast enhancement in
venous phase.
The patient was addressed to the Endocrine Unit for
biochemical evaluation of the adrenal mass.
She was in good clinical conditions and the complete
physical examination was negative; in particular, no Cushing
stigmata or hirsutism was present. Her height was 153 cm,
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Figure 1: Abdominal CT scan with and without contrast enhancement: presence of a big and heterogeneous mass with calcification in left
adrenal lodge (b). Dynamic analysis revealed a progressive and modest contrast enhancement in venous phase (a).
weight 48.5 kg (BMI 20.7 Kg/m2), blood pressure was 110/
70mmHg, pulse rate 64 beats/min, and SpO
2
99% (room air).
There was no family history of relevant morbidities. She was
active smoker and suffered from patent foramen ovale of the
heart and focal nodular hyperplasia of the liver.
Results of the complete blood count, plasma levels of
electrolytes, tests of coagulation, kidney, liver, and thyroid
function were normal. Adrenal function evaluation revealed
that urinary metanephrines and normetanephrines in the
normal range, DHEA-S 1500 ng/ml (350–4300), aldosterone
457.2 pg/ml (37–150), renin 1.5 ng/ml/h (1.0–2.4), aldoster-
one-renin ratio 30.48, basal cortisol, and 17-OH-progesterone
were normal both in basal condition and after stimulation
with ACTH 250mcg. Regrettably the patient was on con-
traceptive estroprogestinic therapy at the time of hormonal
evaluation.
Considering the size and the undetermined radiological
features, the adrenal mass met the criteria for surgical
removal according the most recent international guidelines
[2].
The patient was admitted to the Department of Urology
where she underwent transabdominal adrenalectomy. The
adrenal mass incorporated the renal hilum, aorta, and supe-
rior mesenteric arteria; therefore intraoperative decision to
perform additional left nephrectomy was taken. There were
no complications after surgery.
The surgical sample sent for pathological examination
included left kidney, left adrenal gland, and two lymph nodes
(celiac and paraaortic). The tumor grossly was grey and
multilobulated, replaced the entire adrenal gland, measured
11 × 10 × 7 cm, weighed 195 g, and incorporated arterial and
venous vessels of renal hilum and sparing renal parenchyma.
Figure 2: Histological examination (hematoxylin and eosin stain,
10x): high proportion of ganglion cells (black arrow) in spindle
stroma and dystrophic calcification (white arrow).
The histological report described a spindle cell stroma in a
fibrillarymatrix interspersed with scattered nests of primitive
neuroblasts and high proportion of differentiating elements
(ganglion cells) (Figure 2), placing the tumor in a favorable
subgroup (ganglioneuroblastoma intermixed). Localization
was found in both lymph nodes. These findings were con-
sistent with intermixed stroma-rich ganglioneuroblastoma
(GNB) according to Shimada et al., arising from the adrenal
and with metastatic extension to ipsilateral lymph nodes [3].
The mitosis-karyorrhexis index (MKI) was <2%. In this case,
any N-MYC amplification was detected and any deletion
of the short arm of the chromosome 1. Chemotherapy was
not proposed based on the favorable histology. Any disease
recurrence occurred in the 21-month follow-up from surgery.
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Table 1: Causes of adrenal masses.
(i) Cystic masses: endothelial cyst, pseudocyst, and hydatid cyst
(ii) Solid masses: adenoma, nodular hyperplasia, carcinoma,
metastases, pheochromocytoma, neuroblastic tumors,
neurofibroma, schwannoma, leiomyoma, angiosarcoma,
hamartoma, tuberculoma, and amyloidosis
(iii) Fat-containing masses: lipoma and myelolipoma
Modified from Arnaldi and Boscaro [1].
3. Discussion
Incidentally discovered adrenal masses are becoming more
common with the imaging technological advances and the
increased number of imaging studies performed. Nowadays
the prevalence of adrenal incidentalomas in radiological
studies has come close to the autoptic data: approximately
2–4% in adult age, increasing up to 10% in elderly population.
Their differential diagnosis must consider a wide range of
pathologies (Table 1). The prevalence of different etiologies
varies among the studies; however, it is likely that the major-
ity consists in nonfunctioning adenomas. Other frequently
reported lesions are cortisol secreting adenomas, pheochro-
mocytomas, primitive carcinomas, and distant metastatic
lesions. In a study including 1111 adult patients with adrenal
incidentalomas, GNB was diagnosed in only one case [4]. It
is important to point out that the majority of adrenal lesions
do not come to surgery; therefore pathological diagnoses of
most adrenal incidentalomas remain unknown [1].
Peripheral neuroblastic tumors (PNTs) are a group of
tumors arising from sympathetic ganglion cells. In two-thirds
of the cases, PNTs arise in the adrenal gland or the retroperi-
toneal paravertebral ganglia. PNTs represent one of the most
frequent solid tumors in children, while the occurrence in
adults is very rare. Overall survival in infants is very high
(91%) and progressively declines parallel to the increased
age at diagnosis. In a study performed on RARECAREnet
and involving very few cases, 5-year survival was reported
to be 48% in adolescents (15–24 years) and 40% in adults
(25–64 years) [5].The vast majority of PNTs are sporadic and
family history is reported only in a small percentage of cases
[6]. Conditions such as Hirschsprung’s disease and central
hypoventilation, Turner syndrome, and Neurofibromatosis 1
seem to confer an increased risk of developing neuroblastic
tumors, according to the literature [7–9]. No association
with patent foramen ovale or focal nodular hyperplasia has
been reported. PNTs are made up of two components: neu-
roblastic cells, with different degrees of differentiation, and
Schwannian cells. The International Neuroblastoma Pathol-
ogy Classification (INPC) distinguishes four pathological
groups according to the different proportion of ganglion and
Schwann cells: neuroblastoma (Schwannian stroma-poor,
undifferentiated/poorly, differentiated/differentiating), gan-
glioneuroblastoma intermixed (Schwannian stroma-rich),
ganglioneuroma (Schwannian stroma-dominant), and gan-
glioneuroblastoma nodular (composite Schwannian stroma-
rich/stroma-dominant/stroma-poor) [3]. Clinic presentation
is variable and the most common symptoms include pain or
compression of the abdominal viscera. Metastatic dissemi-
nation occurs in about 40% of patients and involves more
frequently bone and bone marrow. Catecholamines secretion
is documented in more than 70% of cases [10]. The Interna-
tional Neuroblastoma Risk Group Consensus Pretreatment
Classification Scheme defines prognosis and design treat-
ment programs based on the stage of the tumor (according to
the International Neuroblastoma Risk Group Staging System,
INRGSS), age at diagnosis, pathology (INPC), and gene
expression abnormalities (MYCN gene amplification, 11q
aberration, and ploidy) (Table 2) [11]. Therapeutic modalities
include surgery, radiotherapy, and chemotherapy combined
on the basis of the individual patient. Very low risk group
is treated only with surgery, followed by observation. Radio-
therapy and chemotherapy are reserved for the higher risk
groups, combined in different protocols [5].
Revision of the published literature in PubMed retrieved
15 cases of adult-onset adrenal GNB (Table 3) [12, 13]. The
majority of patients were male andmean age at diagnosis was
38.9 years (21–67 years). Clinic was not specific and often
represented by pain or other symptoms due to compression.
Catecholamines secretion was documented only in 4 cases.
Left adrenal gland was more frequently involved, and in one
case bilateral tumors were reported. Imaging features of GNB
varied from oval and homogeneousmasses to heterogeneous,
infiltrating, and calcified lesions. Because most of the lesions
grew silently, at time of diagnosis big masses were found
(mean size 10.44 cm). In locally advanced PNTs with poten-
tially associated surgery-related complications, presurgical
chemotherapy should be administered in order to shrink
the tumor and enable safe resection saving other abdominal
viscera involved [14]. Neuroblastic origin of the tumor was
suspected preoperatively in just few cases, suggesting that
though the radiological appearances of adrenal GNB have
been described in detail [15], the preoperative diagnosis
remains challenging and may be misleading. Consequently
patients were addressed straight to surgery and the definitive
etiology was histologically defined. Metastases were found
at diagnosis in half of the patient and occurred in lymph
nodes, liver, or bonemarrow.The presence ofmetastases does
not seem to correlate with the size or the histopathological
subtype of the tumor. Most of the patients were treated only
with surgery, showing no recurrence during follow-up (mean
follow-up duration 20.9 months). Metastases were detected
after 2.5 years in a patient who refused radio- and chemother-
apy after surgical removal. One patient died 3 months after
diagnosis due to heart failure.
No long-termdata in adults have been reported due to the
small series of patients.
There is no evidence about the most appropriate follow-
up for adrenal GNB in adults.
4 Case Reports in Endocrinology
Ta
bl
e
2:
In
te
rn
at
io
na
lN
eu
ro
bl
as
to
m
aR
isk
G
ro
up
C
on
se
ns
us
Pr
et
re
at
m
en
tC
la
ss
ifi
ca
tio
n
Sc
he
m
e.
IN
RG
St
ag
e
A
ge
(m
on
th
s)
IN
PC
gr
ou
p
G
ra
de
of
di
ffe
re
nt
ia
tio
n
M
YC
N
ge
ne
11
q
ab
er
ra
tio
n
Pl
oi
dy
Pr
et
re
at
m
en
t
ris
k
gr
ou
p
L1
/L
2
G
N
m
at
ur
in
g;
G
N
B
in
te
rm
ix
ed
Ve
ry
lo
w
L1 Lo
ca
liz
ed
tu
m
or
co
nfi
ne
d
to
on
eb
od
y
co
m
pa
rt
m
en
ta
nd
w
ith
ab
se
nc
eo
fi
m
ag
e-
de
fin
ed
ris
k
fa
ct
or
s
A
ny
,e
xc
ep
tG
N
m
at
ur
in
g
or
G
N
B
in
te
rm
ix
ed
N
A
A
m
pl
ifi
ed
Ve
ry
lo
w
H
ig
h
L2 Lo
co
re
gi
on
al
tu
m
or
w
ith
pr
es
en
ce
of
on
eo
rm
or
e
im
ag
e-
de
fin
ed
ris
k
fa
ct
or
<
18
A
ny
,e
xc
ep
tG
N
m
at
ur
in
g
or
G
N
B
in
te
rm
ix
ed
N
A
N
o
Lo
w
Ye
s
In
te
rm
ed
ia
te
≥
18
G
N
B
no
du
la
r;
N
B
D
iff
er
en
tia
tin
g
N
A
N
o
Lo
w
Ye
s
In
te
rm
ed
ia
te
Po
or
ly
di
ffe
re
nt
ia
te
d
or
un
di
ffe
re
nt
ia
te
d
N
A
A
m
pl
ifi
ed
H
ig
h
M D
ist
an
tm
et
as
ta
tic
di
se
as
e(
ex
ce
pt
M
S)
<
18
N
A
H
yp
er
pl
oi
d
Lo
w
<
12
N
A
D
ip
lo
id
In
te
rm
ed
ia
te
12
–1
8
N
A
D
ip
lo
id
In
te
rm
ed
ia
te
<
18
A
m
pl
ifi
ed
H
ig
h
≥
18
H
ig
h
M
S
M
et
as
ta
tic
di
se
as
ec
on
fin
ed
to
sk
in
,l
iv
er
,a
nd
/o
rb
on
e
m
ar
ro
w
in
ch
ild
re
n
<
18
m
on
th
s
N
A
no
Ve
ry
lo
w
ye
s
H
ig
h
A
m
pl
ifi
ed
H
ig
h
IN
RG
:I
nt
er
na
tio
na
lN
eu
ro
bl
as
to
m
a
Ri
sk
G
ro
up
;I
N
CP
:I
nt
er
na
tio
na
lN
eu
ro
bl
as
to
m
a
Pa
th
ol
og
y
Cl
as
sifi
ca
tio
n;
G
N
=
ga
ng
lio
ne
ur
om
a;
G
N
B
=
ga
ng
lio
ne
ur
ob
la
sto
m
a;
N
B
=
ne
ur
ob
la
sto
m
a;
N
A
:n
ot
am
pl
ifi
ed
;
m
od
ifi
ed
fro
m
C
oh
n
et
al
.[
11
].
Case Reports in Endocrinology 5
Ta
bl
e
3:
Re
po
rt
ed
ca
se
so
fa
du
lt-
on
se
ta
dr
en
al
G
N
B
in
lit
er
at
ur
e.
Fi
rs
t
Au
th
or
(y
ea
r)
A
ge
(y
ea
rs
)
G
en
de
r
Sy
m
pt
om
s
Si
ze
(c
m
)
Si
de
Im
ag
in
g
H
or
m
on
al
ac
tiv
ity
M
et
as
ta
se
s
Pr
el
im
in
ar
y
di
ag
no
sis
H
ist
op
at
ho
lo
gy
Tr
ea
tm
en
t
Fo
llo
w
-u
p
Bu
tz
(19
40
)
25
M
Li
ve
r
Ca
m
er
on
(19
67
)
58
F
D
ia
rr
he
a
Ri
gh
t
↑
ur
in
ar
y
ca
te
ch
ol
am
in
es
,
va
ni
lm
an
de
lic
ac
id
an
d
ho
m
ov
an
ilm
an
-
de
lic
ac
id
Ab
se
nt
Ph
eo
ch
ro
m
oc
yt
om
a
Su
rg
er
y
3.
5y
ea
rs
,n
o
re
cu
rr
en
ce
Ta
ka
ha
sh
i
(19
88
)
21
M
As
ym
pt
om
at
ic
8,
8
Le
ft
↑
ur
in
ar
y
va
ni
lm
an
de
lic
ac
id
Ly
m
ph
no
de
s
N
eu
ro
bl
as
to
m
a
Su
rg
er
y
+
RT
+
CT
8
m
on
th
s,
no
re
cu
rr
en
ce
Ko
iz
um
i
(19
92
)
47
F
Fa
tig
ue
,l
ow
ba
ck
pa
in
9
Ri
gh
t
H
et
er
og
en
eo
us
↑
ur
in
ar
y
ca
te
ch
ol
am
in
es
,
va
ni
lm
an
de
lic
ac
id
an
d
ho
m
ov
an
ilm
an
-
de
lic
ac
id
Bo
ne
m
ar
ro
w
N
on
e
N
on
e
3
m
on
th
s,
de
ad
H
ig
uc
hi
(19
93
)
29
M
11
↑
ur
in
ar
y
ca
te
ch
ol
am
in
es
Bo
ne
m
ar
ro
w
Su
rg
er
y
10
m
on
th
s,
no
re
cu
rr
en
ce
H
iro
sh
ig
e
(19
95
)
35
M
As
ym
pt
om
at
ic
10
Le
ft
H
et
er
og
en
eo
us
an
d
ca
lc
ifi
ca
tio
ns
N
on
e
Ab
se
nt
Ca
rc
in
om
a,
ne
ur
ob
la
sto
m
a
Su
rg
er
y
2
ye
ar
s,
no
re
cu
rr
en
ce
M
eh
ta
(19
97
)
22
M
9
Bi
la
te
ra
l
Su
rg
er
y
Ro
us
se
au
(19
98
)
F
Le
ft
Li
ve
r
Su
rg
er
y
+
RT
+
CT
Fu
jiw
ar
a
(2
00
0)
25
M
H
ea
da
ch
e,
pa
lp
ita
tio
ns
,
hy
pe
rt
en
sio
n,
w
ei
gh
tl
os
s
9
Le
ft
O
va
la
r,
he
te
ro
ge
ne
ou
s,
ca
lc
ifi
ca
tio
ns
N
on
e
Ab
se
nt
Ph
eo
ch
ro
m
oc
yt
om
a
G
N
B
in
te
rm
ix
ed
+
ph
eo
ch
ro
m
oc
yt
om
a
Su
rg
er
y
5
ye
ar
s,
no
re
cu
rr
en
ce
Sl
ap
a
(2
00
2)
20
F
As
ym
pt
om
at
ic
18
N
on
e
Ab
se
nt
Su
rg
er
y
1y
ea
r,
no
re
cu
rr
en
ce
Ko
ik
e
(2
00
3)
5 0
M
As
ym
pt
om
at
ic
4,
5
Ri
gh
t
O
va
la
r,
ne
cr
ot
ic
ce
nt
ra
la
re
a
N
on
e
Ph
eo
ch
ro
m
oc
yt
om
a,
ad
re
na
lm
al
ig
na
nc
y,
ne
ur
ob
la
st
ic
tu
m
or
Su
rg
er
y
2.
5y
ea
rs
,n
o
re
cu
rr
en
ce
G
un
lu
so
y
(2
00
4)
59
M
Ri
gh
tfl
an
k
an
d
ep
ig
as
tr
ic
pa
in
,
m
al
ai
se
,a
ne
m
ia
,
w
ei
gh
tl
os
s,
m
ic
ro
sc
op
ic
he
m
at
ur
ia
12
Ri
gh
t
Lo
bu
la
te
d,
ne
cr
ot
ic
ar
ea
s
N
on
e
Ly
m
ph
no
de
s
N
on
e
Su
rg
er
y
M
iz
un
o
(2
01
0)
53
M
In
cr
ea
se
d
fre
qu
en
cy
of
ur
in
at
io
n
11
Ri
gh
t
Sm
oo
th
m
ar
gi
ns
,
ho
m
og
en
eo
us
N
on
e
Lu
m
ba
r
sp
in
e
N
on
e
G
N
B
no
du
la
r
Su
rg
er
y
Re
cu
rr
en
ce
aft
er
2.
5
ye
ar
s
6 Case Reports in Endocrinology
Ta
bl
e
3:
C
on
tin
ue
d.
Fi
rs
t
Au
th
or
(y
ea
r)
A
ge
(y
ea
rs
)
G
en
de
r
Sy
m
pt
om
s
Si
ze
(c
m
)
Si
de
Im
ag
in
g
H
or
m
on
al
ac
tiv
ity
M
et
as
ta
se
s
Pr
el
im
in
ar
y
di
ag
no
sis
H
ist
op
at
ho
lo
gy
Tr
ea
tm
en
t
Fo
llo
w
-u
p
Bo
lza
cc
hi
ni
(2
01
5)
63
M
As
ym
pt
om
at
ic
5
Le
ft
Ir
re
gu
la
rm
ar
gi
ns
,
he
te
ro
ge
ne
ou
s
N
on
e
Ab
se
nt
N
on
e
G
N
B
no
du
la
r
Su
rg
er
y
6
m
on
th
s,
no
re
cu
rr
en
ce
Q
iu
(2
01
5)
27
F
Pa
in
11
Le
ft
O
va
la
r,
cy
st
ic
-s
ol
id
N
on
e
Ab
se
nt
Ph
eo
ch
ro
m
oc
yt
om
a
G
N
B
in
te
rm
ix
ed
Su
rg
er
y
5
m
on
th
s,
no
re
cu
rr
en
ce
Pr
es
en
t
ca
se
(2
01
5)
21
F
As
ym
pt
om
at
ic
11
Le
ft
Lo
bu
la
te
d,
he
te
ro
ge
ne
ou
s,
ca
lc
ifi
ca
tio
ns
N
on
e
Ly
m
ph
no
de
s
Ad
re
na
lc
ar
ci
no
m
a,
le
io
m
yo
sa
rc
om
a
G
N
B
in
te
rm
ix
ed
Su
rg
er
y
21
m
on
th
s,
no
re
cu
rr
en
ce
M
od
ifi
ed
fro
m
Bo
lza
cc
hi
ni
et
al
.[
12
,1
3]
.
Case Reports in Endocrinology 7
Consent
Written informed consent was obtained from the patient for
publication of this case report and any accompanying images.
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